Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

二、药品的其他相关情况 公司精蛋白人胰岛素混合注射液，适用于 1 型或 2 型糖尿病。主要成份为人 胰岛素，通过基因重组技术生产，它能促进肝脏、肌肉和脂肪等组织摄取和利用 葡萄糖，抑制肝糖原分解及糖异生作用，从而降低血糖水平。精蛋白可使胰岛素 缓慢释放，延长其作用时间。 尼加拉瓜位于中美洲中部，地处连接南北美洲的战略位置，是"一带一路" 沿线的新兴市场。尼加拉瓜是中美洲面积最大的国家并且人口稳步增长，截至 2023 年 7 月，总人口约 684.4 万人。近年来，人口老龄化和慢性病患者数量的增加推 动尼加拉瓜医疗需求持续提升。国际糖尿病联盟（IDF）发布的全球糖尿病概览 第 11 版（2024）数据显示，2024 年尼加拉瓜 20-79 岁的糖尿病患者规模上升至 1 证券代码：600867 证券简称：通化东宝 公告编号：2025-033 通化东宝药业股份有限公司 关于精蛋白人胰岛素注射液 获得境外药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于近日 ...

美国当地时间5月11日，美国总统特朗普在社交平台Truth Social发文称，5月12日上午9时(北京时间5月 12日21时)将在白宫签署"美国历史上最具影响力的行政命令之一"，处方药和医药产品价格"几乎会立即 下降30%至80%"，称以"最惠国政策"规定美国所支付的药品价格将与全球支付最低价格的国家相同。5 月12日，国内胰岛素企业通化东宝（600867）回应称，目前公司没有在美销售的产品，短期内不受该政 策影响。公司已具备规模化生产的技术壁垒，未来随着门冬、甘精、赖脯3款胰岛素在美国布局的推 进，凭借该优势，预计依然可以为公司带来可观的利润空间。此外，美国的药品审批体系在发展中国家 认可度较高，公司希望通过美国的获批，加速在新兴市场及部分共建"一带一路"国家的注册审批进度， 快速覆盖相关市场。(每日经济新闻) ...

Core Viewpoint - The company reported a significant decline in net profit for 2024, attributed to the implementation of a new round of insulin centralized procurement, which led to price reductions and decreased sales revenue [2][5][6]. Group 1: Financial Performance - The company achieved a net profit attributable to shareholders of -42.72 million yuan, a year-on-year decrease of 103.66% [2]. - The net profit after deducting non-recurring gains and losses was -9.19 million yuan, also showing a year-on-year decline [2]. - The decline in profit was influenced by the new insulin centralized procurement, which resulted in lower prices for insulin products and affected sales revenue [5][6]. Group 2: Business Strategy and Market Position - The company successfully secured A-class bids for its entire range of insulin products in the latest centralized procurement, significantly increasing its market access [7]. - The company plans to implement a "volume protection and expansion" strategy to ensure the execution of approximately 45 million units of agreement volume while focusing on retail and untapped market areas [8]. - The company holds over 40% market share in the human insulin market, maintaining its position as the industry leader [8]. Group 3: Product Development and Innovation - The company launched several new products, including GLP-1 receptor agonists and SGLT-2 inhibitors, which are expected to enhance its product portfolio and market presence [9][10]. - The company is actively expanding its research and development in the endocrine metabolism field, with ongoing projects for new drugs targeting diabetes and hyperuricemia [9][10]. Group 4: International Expansion - The company achieved 103 million yuan in overseas market revenue in 2024, marking an almost 80% increase year-on-year [18]. - Strategic partnerships have been established to enter the U.S. insulin market, and the company is preparing registration materials for various products in developing countries [18]. Group 5: Human Capital and Organizational Development - The company is focusing on talent recruitment and performance management to enhance its operational efficiency and support its strategic goals [19][20]. - A comprehensive talent development mechanism is being implemented to improve employee capabilities and align individual goals with company objectives [20][29]. Group 6: Governance and Compliance - The company has adhered to legal and regulatory requirements in its operations, ensuring transparency and protecting shareholder interests [22][24]. - The board of directors has conducted multiple meetings to review and approve significant operational decisions, maintaining a structured governance framework [22][23].

通化东宝药业股份有限公司 2024 年年度股东大会会议资料 股票简称：通化东宝 股票代码：600867 二〇二五年五月二十一日 1 通化东宝药业股份有限公司 2024 年年度股东大会会议议程 一、会议时间： 二、会议召开地点：公司会议室 三、会议议程： 现场会议时间：2025 年 5 月 21 日上午 10 时 网络投票时间：网络投票起止时间：自 2025 年 5 月 21 日 至 2025 年 5 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （一）主持人宣布会议开始 （二）推选股东大会监票人和计票人 （三）会议审议内容： | 序号 | 议案名称 | | --- | --- | | | 非累积投票议案 | | 1 | 《2024 年度董事会工作报告》 | | 2 | 《2024 年度监事会工作报告》 | | 3 | 《2024 年年度报告及报告摘要》 | | 4 | 《2024 年度财务决算报告》 | ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-032 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 623,593,436 股，占公司目前股份总额的 31.84%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 551,439,472 股，占 其及一致行动人所持有公司股份总额的 88.43%，占公司目前股份总额的 28.16%。 其中：东宝集团持有公司股份 601,731,257 股，占公司目前股份总额的 30.72%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 551,439,472 股， 占其所持有公司股份总额的 91.64%，占公司目前股份总额的 28.16%。 2025 年 5 月 8 日,本公司接到东宝集团关于股份解押及再质押相关情况的 ...

Core Viewpoint - Tonghua Dongbao's performance faced short-term pressure in 2024 due to insulin price cuts, strategic termination of R&D projects, and litigation costs, but showed strong recovery in Q1 2025 with double-digit revenue growth driven by increased product sales and market share [1][2][3][8] Group 1: 2024 Performance Challenges - The net profit decline in 2024 was primarily due to three factors: insulin price adjustments leading to revenue shrinkage, strategic termination of the soluble double insulin injection project resulting in a profit reduction of approximately 215 million yuan, and litigation costs of about 61.31 million yuan [2] - Despite these challenges, the company's market share in insulin continued to rise, reaching 43.7%, maintaining its position as the leader in the domestic market [2] Group 2: Q1 2025 Recovery - In Q1 2025, the company achieved revenue of 652 million yuan, a year-on-year increase of 10.17% and a quarter-on-quarter increase of 15.97%, indicating a recovery to levels similar to Q1 2023 [3] - Key factors for this recovery included successful continuation of insulin procurement contracts, with a signed volume of 45 million units, and a significant increase in the number of hospitals carrying the company's products [3][4] Group 3: Product and Market Development - The company experienced a 123% increase in overall insulin product sales, with the Aspart series seeing a remarkable 260% year-on-year growth, optimizing the product structure [3] - The overseas revenue reached 58 million yuan in Q1 2025, exceeding 50% of the total overseas revenue for 2024 [4] Group 4: R&D and Innovation - The company increased R&D investment to 450 million yuan in 2024, a year-on-year growth of 7.15%, with R&D expenses accounting for 22.42% of revenue [5] - Several products are in advanced clinical stages, including GLP-1 products and gout medications, indicating a robust pipeline for future growth [5] Group 5: Global Expansion Strategy - The company is accelerating its global expansion, with progress in product registration in various countries, including Uzbekistan and the EU, and a tailored "going global" strategy [6][7] - The strategy includes exporting raw materials and establishing partnerships for market development, focusing on insulin and GLP-1 products in emerging markets [7] Group 6: Future Outlook - 2025 is seen as a pivotal year for the company, with expected benefits from insulin procurement contracts and hospital access expansion, alongside long-term growth from innovative drug pipelines and international market expansion [8] - The combination of a solid insulin base, innovative drugs in the metabolic field, and a clear global strategy positions the company for sustainable returns for investors [8]

2025年4月30日，通化东宝(600867.SH)发布2025年第一季报。截至2025年4月30日，共有14个机构投资 者披露持有通化东宝A股股份，合计持股量达9.07亿股，占通化东宝总股本的46.33%。其中，前十大机 构投资者包括东宝实业集团股份有限公司、天津桢逸股权投资合伙企业(有限合伙)、阿布达比投资局、 中国银行股份有限公司-招商国证生物医药指数分级证券投资基金、香港中央结算有限公司、中国农业 银行股份有限公司-中证500交易型开放式指数证券投资基金、上海银行股份有限公司-银华中证创新药 产业交易型开放式指数证券投资基金、中信建投证券股份有限公司-天弘国证生物医药交易型开放式指 数证券投资基金、通化吉祥创赢投资管理中心、九泰久睿量化A，前十大机构投资者合计持股比例达 46.31%。相较于上一季度，前十大机构持股比例合计上涨了0.48个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计2个，包括创新药、天弘国证生物医药ETF，持 股增加占比小幅上涨。本期较上一季度持股减少的公募基金共计2个，包括南方中证500ETF、招商国证 生物医药指数A，持股减少占比达0.15%。本期较上一季度新披露的公 ...

Core Viewpoint - Tonghua Dongbao reported a significant decline in revenue and net profit for 2024, primarily due to adverse factors such as the impact of centralized procurement and the termination of R&D projects, but showed signs of recovery in early 2025 with a revenue increase [1][2]. Financial Performance - In 2024, the company achieved revenue of 2.01 billion yuan, a year-on-year decrease of 34.66% [1] - The net profit attributable to shareholders was a loss of 43 million yuan, with a non-recurring net profit loss of 9 million yuan [1] - For the first half of 2024, revenue was 740 million yuan, while the second half saw a revenue of 1.27 billion yuan, representing a quarter-on-quarter increase of 71.55% [1] - The first quarter of 2025 showed a revenue increase of 10.17% year-on-year [1] Market Expansion - The new round of centralized procurement accelerated the market entry and volume growth of Tonghua Dongbao's insulin products, with significant new hospital admissions: approximately 1,400 for glargine insulin, 3,000 for aspart insulin, and 5,000 for premixed aspart insulin [1][2] - The total signed volume for insulin products in the latest procurement round reached approximately 45 million units, marking a substantial increase compared to the previous round [2] R&D and Innovation - The company is advancing its core pipeline, with promising clinical data for its GLP-1/GIP dual-target receptor agonist (THDBH120) and successful completion of key clinical trials for other innovative products [3] - The R&D expenses accounted for 22.42% of revenue in 2024, indicating a continued commitment to high R&D investment [4] - The company is expanding its treatment areas beyond diabetes to include gout and hyperuricemia, while exploring products with multiple indications such as glucose reduction and weight loss [4] Future Outlook - The company is expected to experience a commercial explosion of several key products between 2025 and 2027, creating a positive growth pattern of stable growth from existing products and rapid breakthroughs from new products [3]